Apoptosis of oligodendrocytes in the central nervous system results in rapid focal demyelination

Annals of Neurology

Volumn 72, Issue 3, 2012, Pages 395-405

  Caprariello, Andrew V ^a   Mangla, Saisho ^a   Miller, Robert H ^a   Selkirk, Stephen M ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 9; COMPLEMENTARY DNA; MYELIN BASIC PROTEIN;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN VENTRICLE; CELL INFILTRATION; CELL PROLIFERATION; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEMYELINATION; ENZYME ACTIVATION; GLIOSIS; MULTIPLE SCLEROSIS; NONHUMAN; OLIGODENDROGLIA; PRIORITY JOURNAL; RAT;

ANIMALS; APOPTOSIS; APOPTOTIC PROTEASE-ACTIVATING FACTOR 1; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BRAIN; CASPASE 9; CELL COUNT; CELLS, CULTURED; DEMYELINATING DISEASES; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; GANGLIOSIDES; GLIAL FIBRILLARY ACIDIC PROTEIN; GLIOTOXIN; GREEN FLUORESCENT PROTEINS; IMMUNOSUPPRESSIVE AGENTS; MYELIN BASIC PROTEIN; NERVE TISSUE PROTEINS; O ANTIGENS; OLIGODENDROGLIA; PROTEIN MULTIMERIZATION; RATS; TACROLIMUS; TRANSDUCTION, GENETIC; TRANSFECTION;

EID: 84867046355     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.23606     Document Type: Article

References (39)

1. Martin R, McFarland HF, McFarlin DE,. Immunological aspects of demyelinating diseases. Annu Rev Immunol 1992; 10: 153-187.
2. Wang Y, Wu C, Caprariello AV, et al. In vivo quantification of myelin changes in the vertebrate nervous system. J Neurosci 2009; 29: 14663-14669.
3. Blakemore WF, Franklin RJ,. Remyelination in experimental models of toxin-induced demyelination. Curr Top Microbiol Immunol 2008; 318: 193-212.
4. Waksman BH, Porter H, Lees MD, et al. A study of the chemical nature of components of bovine white matter effective in producing allergic encephalomyelitis in the rabbit. J Exp Med 1954; 100: 451-471.
5. Linington C, Lassmann H, Ozawa K, et al. Cell adhesion molecules of the immunoglobulin supergene family as tissue-specific autoantigens: induction of experimental allergic neuritis (EAN) by P0 protein-specific T cell lines. Eur J Immunol 1992; 22: 1813-1817.
6. Linington C, Berger T, Perry L, et al. T cells specific for the myelin oligodendrocyte glycoprotein mediate an unusual autoimmune inflammatory response in the central nervous system. Eur J Immunol 1993; 23: 1364-1372.
7. Wekerle H, Kojima K, Lannes-Vieira J, et al. Animal models. Ann Neurol 1994; 36 (suppl): S47-S53.
8. van Oosten BW, Lai M, Hodgkinson S, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 1997; 49: 351-357.
9. Sriram S, Steiner I,. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol 2005; 58: 939-945.
10. Breij EC, Brink BP, Veerhuis R, et al. Homogeneity of active demyelinating lesions in established multiple sclerosis. Ann Neurol 2008; 63: 16-25.
11. Lucchinetti C, Bruck W, Parisi J, et al. A quantitative analysis of oligodendrocytes in multiple sclerosis lesions. A study of 113 cases. Brain 1999; 122 (pt 12): 2279-2295.
12. Lucchinetti C, Bruck W, Parisi J, et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol 2000; 47: 707-717.
13. Barnett MH, Prineas JW,. Relapsing and remitting multiple sclerosis: pathology of the newly forming lesion. Ann Neurol 2004; 55: 458-468.
14. Yao DL, Webster HD, Hudson LD, et al. Concentric sclerosis (Balo): morphometric and in situ hybridization study of lesions in six patients. Ann Neurol 1994; 35: 18-30.
15. Stadelmann C, Ludwin S, Tabira T, et al. Tissue preconditioning may explain concentric lesions in Balo's type of multiple sclerosis. Brain 2005; 128 (pt 5): 979-987.
16. Goujet-Zalc C, Babinet C, Monge M, et al. The proximal region of the MBP gene promoter is sufficient to induce oligodendroglial-specific expression in transgenic mice. Eur J Neurosci 1993; 5: 624-632.
17. Coleman JE, Huentelman MJ, Kasparov S, et al. Efficient large-scale production and concentration of HIV-1-based lentiviral vectors for use in vivo. Physiol Genomics 2003; 12: 221-228.
18. Straathof KC, Pule MA, Yotnda P, et al. An inducible caspase 9 safety switch for T-cell therapy. Blood 2005; 105: 4247-4254.
19. Fyffe-Maricich SL, Karlo JC, Landreth GE, et al. The ERK2 mitogen-activated protein kinase regulates the timing of oligodendrocyte differentiation. J Neurosci 2011; 31: 843-850.
20. Caprariello AV, Miller RH, Selkirk SM,. Foamy virus as a gene transfer vector to the central nervous system. Gene Ther 2009; 16: 448-452.
21. Matsushima GK, Morell P,. The neurotoxicant, cuprizone, as a model to study demyelination and remyelination in the central nervous system. Brain Pathol 2001; 11: 107-116.
22. Artemiadis AK, Anagnostouli MC,. Apoptosis of oligodendrocytes and post-translational modifications of myelin basic protein in multiple sclerosis: possible role for the early stages of multiple sclerosis. Eur Neurol 2010; 63: 65-72.
23. Henderson AP, Barnett MH, Parratt JD, et al. Multiple sclerosis: distribution of inflammatory cells in newly forming lesions. Ann Neurol 2009; 66: 739-753.
24. Barnett MH, Parratt JD, Pollard JD, et al. MS: is it one disease? Int MS J 2009; 16: 57-65.
25. Psachoulia K, Jamen F, Young KM, Richardson WD,. Cell cycle dynamics of NG2 cells in the postnatal and ageing brain. Neuron Glia Biol 2009; 5: 57-67.
26. Woodruff RH, Fruttiger M, Richardson WD, Franklin RJ,. Platelet-derived growth factor regulates oligodendrocyte progenitor numbers in adult CNS and their response following CNS demyelination. Mol Cell Neurosci 2004; 25: 252-262.
27. Yang Y, Lewis R, Miller RH,. Interactions between oligodendrocyte precursors control the onset of CNS myelination. Dev Biol 2011; 350: 127-138.
28. Patrikios P, Stadelmann C, Kutzelnigg A, et al. Remyelination is extensive in a subset of multiple sclerosis patients. Brain 2006; 129: 3165-3172.
29. Neumann H, Kotter MR, Franklin RJ,. Debris clearance by microglia: an essential link between degeneration and regeneration. Brain 2009; 132 (pt 2): 288-295.
30. Block ML, Zecca L, Hong JS,. Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007; 8: 57-69.
31. Chen J, Zhou Y, Mueller-Steiner S, et al. SIRT1 protects against microglia-dependent amyloid-beta toxicity through inhibiting NF-kappaB signaling. J Biol Chem 2005; 280: 40364-40374.
32. Streit WJ,. Microglia and neuroprotection: implications for Alzheimer's disease. Brain Res Brain Res Rev 2005; 48: 234-239.
33. Pohl HB, Porcheri C, Mueggler T, et al. Genetically induced adult oligodendrocyte cell death is associated with poor myelin clearance, reduced remyelination, and axonal damage. J Neurosci 2011; 31: 1069-1080.
34. Traka M, Arasi K, Avila RL, et al. A genetic mouse model of adult-onset, pervasive central nervous system demyelination with robust remyelination. Brain 2010; 133: 3017-3029.
35. Zitvogel L, Kepp O, Kroemer G,. Decoding cell death signals in inflammation and immunity. Cell 2010; 140: 798-804.
36. Ghiringhelli F, Apetoh L, Tesniere A, et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009; 15: 1170-1178.
37. Elliott MR, Chekeni FB, Trampont PC, et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009; 461: 282-286.
38. Ronchetti A, Rovere P, Iezzi G, et al. Immunogenicity of apoptotic cells in vivo: role of antigen load, antigen-presenting cells, and cytokines. J Immunol 1999; 163: 130-136.
39. Tsutsui S, Stys PK,. Degeneration versus autoimmunity in multiple sclerosis. Ann Neurol 2009; 66: 711-713.